ArticleFrontiers in oncology2025
FGF21 inhibits invasion and metastasis via IL-17A-Notch in pancreatic ductal adenocarcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) demonstrates characteristic histopathological features marked by abundant inflammatory cell infiltration and the formation of dense fibrous stromal capsules, which contribute to its aggressive metastatic potential. Although Fibroblast Growth Factor 21(FGF21) exhibits pancreatic anti-inflammatory properties, its expression becomes markedly downregulated in PDAC. The present research explores the inhibitory effects of FGF21 on PDAC progression within inflammatory microenvironments, with particular focus on delineating the involved signaling pathways and molecular interactions. Methods: We detected FGF21 expression in human PDAC specimens and analyzed its relationship with various clinicopathological features. For Results: Low expression of FGF21 in PDAC patients is associated with higher TNM stages and increased rates of lymph node metastasis, vascular invasion, and tumor recurrence compared to high expression of FGF21. Conclusion: FGF21 suppresses invasion and metastasis in PDAC by inhibiting the IL-17A-Notch signaling axis, which reveals a novel therapeutic strategy for this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.